Italy is an important pharmaceutical market in Europe, but obtaining marketing authorization is only one part of bringing a medicine to patients. Companies must understand the applicable authorization route, prepare a compliant regulatory dossier, and plan for national pricing and reimbursement requirements.
The Italian Medicines Agency (AIFA) plays a central role in evaluating medicines, assessing their therapeutic value, and managing pricing and reimbursement decisions for products within its remit. These processes operate alongside European authorization procedures and regional healthcare implementation.
For companies planning Italy drug approval, understanding the relationship between authorization, health technology assessment (HTA), pricing, reimbursement, and access planning is essential. Changes introduced during 2026 make it particularly important to prepare clinical and economic evidence early.
Is AIFA Approval the Same as Marketing Authorisation in Italy?
No. Marketing authorization and AIFA’s pricing and reimbursement decisions are separate regulatory and market-access steps. The applicable marketing authorization route depends on the medicine, its intended use, and the markets in which the applicant seeks approval.
The main routes are:
- Centralised procedure: The European Medicines Agency (EMA) conducts the scientific assessment, and the European Commission grants the marketing authorization. The authorization applies across the EU.
- National procedure: The applicant seeks authorization in Italy through the national regulatory framework.
- Decentralised procedure (DCP): The applicant seeks authorization in multiple EU Member States simultaneously for a medicine that has not yet been authorized in the EU and does not fall under the mandatory centralised procedure.
- Mutual recognition procedure (MRP): Other Member States recognize an existing authorization granted by one Member State, subject to the applicable procedure.
A medicine authorized through the centralised procedure does not need a separate Italian marketing authorization. However, authorization does not automatically establish its price, reimbursement status, or practical availability within Italy’s healthcare system. For products seeking publicly funded access, the relevant pricing and reimbursement process must also be addressed. This is where AIFA HTA, clinical evidence, economic evaluation, and negotiations can become important.
What Are the Main Regulatory Steps for Launching a Medicine in Italy?
Italy pharmaceutical regulation requires companies to coordinate dossier preparation, the relevant authorization procedure, and subsequent market-access activities.
- Confirm the applicable authorization route
Determine whether the product falls under the centralised, national, DCP, or MRP pathway. The route influences submission requirements, assessment responsibilities, and the relationship between national and European regulatory processes. - Prepare a compliant regulatory dossier
The application generally follows the Common Technical Document (CTD) structure, covering administrative information, quality, nonclinical data, and clinical evidence as applicable. The dossier should be internally consistent and supported by appropriate evidence. Attention should be given to product information, manufacturing and quality documentation, clinical data, and the requirements of the selected procedure. - Address Italian requirements
Applicants should assess the applicable Italian-language product information, national administrative requirements, and any procedure-specific documentation. These requirements should be identified early rather than treated as final submission tasks. - Complete the marketing authorization process
The competent authority or authorities assess the application under the relevant procedure. Depending on the route, this may involve national assessment, coordination between Member States, or an EU-level assessment and decision. - Plan for pricing and reimbursement
For products intended to receive public reimbursement, companies should prepare for the applicable AIFA pricing and reimbursement process. Clinical value, unmet medical need, comparative evidence, and economic considerations may influence the assessment.
What Happens After Marketing Authorisation?
Marketing authorization establishes that a medicine can be placed on the market under the conditions of its authorization. It does not, by itself, guarantee public reimbursement or uniform access across Italy. For products seeking reimbursement, companies may need to submit a separate pricing and reimbursement application to AIFA. The assessment may consider the medicine’s therapeutic value, available alternatives, comparative clinical evidence, budget implications, and proposed price.
The process can include:
- Clinical and therapeutic assessment: Evaluation of the medicine’s benefits, risks, and place in therapy.
- Health technology assessment: Review of relevant clinical and economic evidence under the applicable framework.
- Pricing and reimbursement assessment: Consideration of the requested price and reimbursement conditions.
- Negotiation and decision-making: Determination of the applicable pricing and reimbursement outcome.
- Regional implementation: Consideration of regional and local healthcare arrangements that may affect practical availability.
The precise steps and documentation depend on the product and the applicable procedure. Some medicines may follow specific or simplified pathways where the relevant eligibility conditions are met. Companies should therefore distinguish between regulatory authorization, national reimbursement status, and implementation within the healthcare system. Treating these as a single milestone can create unrealistic launch timelines.
What Changed in AIFA's P&R/HTA Process in 2026?
Several 2026 developments are relevant to companies preparing Italy market access strategies.
- Updated HTA dossier guidelines
AIFA’s updated guidelines for pricing and reimbursement applications, established under Resolution No. 88/2025, became applicable on 1 April 2026. The updated framework affects how applicants prepare and present the evidence required for assessment.
Applicants should consult the current AIFA guidance rather than rely on older dossier templates. The applicable requirements depend on the type of application and the relevant procedure.
Official guidance: AIFA — Pricing and reimbursement applications - Changes to simplified and fast-track procedures
AIFA has also developed distinct pathways for eligible applications. Simplified procedures and fast-track procedures should not be treated as interchangeable: their eligibility conditions, assessment arrangements, and decision-making requirements differ. - September 2026 e-Dossier update and EU Joint Clinical Assessment
AIFA updated its e-Dossier materials in September 2026 to address requirements associated with Regulation (EU) 2021/2282 on health technology assessment, including Joint Clinical Assessment (JCA) fields for relevant applications. The implications depend on the medicine and its JCA status. Applicants should determine which clinical evidence, and documentation requirements apply to their specific application instead of assuming that one set of requirements covers every product. The practical priority is to align the regulatory dossier, clinical evidence strategy, and pricing and reimbursement submission early. This can reduce the risk of inconsistencies or additional work when moving from authorization planning to market access.
Official reference: AIFA — Pricing and reimbursement applications and e-Dossier resources
How Does AIFA Determine Pharmaceutical Value?
AIFA’s assessment of pharmaceutical value depends on the applicable procedure and the evidence submitted. For pricing and reimbursement decisions, the evaluation can extend beyond whether a medicine has demonstrated efficacy and safety.
Relevant considerations may include:
- Therapeutic need: The seriousness of the condition and the availability and limitations of existing treatment options.
- Added therapeutic benefit: The extent to which the medicine improves outcomes compared with relevant alternatives.
- Quality of clinical evidence: The strength, relevance, and reliability of the available evidence.
- Economic considerations: The proposed price, cost-effectiveness evidence where relevant, and potential budget impact.
- Place in therapy: The medicine’s expected role in clinical practice and its potential effect on treatment pathways.
For medicines seeking recognition of innovative status, AIFA applies specific criteria relating to therapeutic need, added therapeutic benefit, and the quality of scientific evidence. Innovation should not be assumed solely because a medicine uses a new mechanism or technology. A strong submission should explain the clinical evidence in context, justify the proposed value, and clearly connect the evidence to the requested pricing and reimbursement conditions. Where economic analyses are relevant, assumptions and comparisons should be transparent and supported by appropriate data.
Why Italy Market Entry Requires Regulatory and Market-Access Alignment
Regulatory authorization and market access have different objectives, but they are closely connected. A dossier may support a positive marketing authorization decision without fully addressing the comparative clinical or economic questions relevant to reimbursement. If these evidence needs are identified late, companies may face additional analysis, revised documentation, or delays in their access strategy.
Regional healthcare arrangements also matter. A national decision does not mean that every region or healthcare facility will implement access in the same way or at the same time. Local formularies, procurement processes, and care pathways may affect the practical availability of a medicine.
A coordinated Italy market entry strategy should therefore:
- Confirm the authorization route and its requirements.
- Identify the clinical and economic evidence needed for the intended access pathway.
- Align product information and regulatory documentation.
- Prepare pricing and reimbursement materials using current AIFA guidance.
- Account for relevant regional implementation and procurement considerations.
- Assign clear responsibilities across regulatory, medical, market-access, and commercial teams.
The 2026 Italy Regulatory-to-Access Roadmap
A structured roadmap can help companies coordinate Italy drug approval and subsequent market-access activities.
Step 1: Define the authorization route
Confirm whether the product requires a centralised, national, DCP, or MRP pathway and identify the relevant regulatory responsibilities.
Step 2: Assess dossier readiness
Review the CTD, product information, quality documentation, and clinical evidence for completeness and consistency.
Step 3: Identify current AIFA requirements
Check the latest pricing and reimbursement guidance, e-Dossier requirements, and the eligibility criteria for any relevant simplified or fast-track procedure.
Step 4: Build the evidence strategy
Assess comparative clinical evidence, unmet medical need, therapeutic positioning, and economic evidence relevant to the intended access pathway.
Step 5: Coordinate regulatory and market-access teams
Ensure that the regulatory dossier, clinical narrative, proposed value, and reimbursement strategy are consistent.
Step 6: Plan post-authorization activities
Establish a realistic sequence for pricing and reimbursement submissions, applicable negotiations, and relevant regional implementation activities.
Step 7: Monitor regulatory changes
Track changes to AIFA guidance and applicable EU requirements so that submission plans and supporting documentation remain current.
Learn more: DDReg — Regulatory Services in Italy.
Conclusion
Successful entry into the Italian pharmaceutical market requires more than obtaining marketing authorization. Companies need to understand the applicable regulatory route, prepare a robust dossier, and plan for the separate requirements governing pricing, reimbursement, and practical access.
The 2026 changes to AIFA’s dossier guidance and e-Dossier resources make current requirements and early evidence planning particularly important. Aligning regulatory and market-access activities can help companies build a more realistic launch strategy and reduce avoidable delays.
For organizations planning Italy drug approval or coordinating submissions across European markets, a clear regulatory-to-access roadmap provides a practical foundation for compliant and sustainable market entry.
Frequently Asked Questions
AIFA is Italy’s national medicines agency. Its responsibilities include evaluating medicines under the applicable national framework and managing relevant pricing and reimbursement activities. The marketing authorization decision itself depends on the route used: for example, the European Commission grants authorizations under the EU centralised procedure.
A separate Italian marketing authorization is not required for a medicine authorized through the EU centralised procedure. Other authorization routes, including national, decentralised, and mutual recognition procedures, operate under their respective frameworks.
No. Marketing authorization and pricing and reimbursement are separate decisions. Products seeking public reimbursement must address the applicable AIFA process, and practical access may also depend on regional healthcare arrangements.
Relevant developments include updated pricing and reimbursement dossier guidelines applicable from 1 April 2026, distinct simplified and fast-track procedures, and September 2026 e-Dossier updates addressing requirements associated with EU Joint Clinical Assessment. Applicants should verify the current AIFA guidance and the requirements applicable to their specific product.
Depending on the application, relevant evidence may include clinical efficacy and safety, comparative therapeutic benefit, unmet medical need, scientific evidence quality, and economic information supporting the proposed price and reimbursement conditions.